210 related articles for article (PubMed ID: 19075280)
1. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
Lamanna N; Jurcic JG; Noy A; Maslak P; Gencarelli AN; Panageas KS; Heaney ML; Brentjens RJ; Golde DW; Scheinberg DA; Zelenetz AD; Weiss MA
J Clin Oncol; 2009 Feb; 27(4):491-7. PubMed ID: 19075280
[TBL] [Abstract][Full Text] [Related]
2. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW
Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
5. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
Faderl S; Wierda W; O'Brien S; Ferrajoli A; Lerner S; Keating MJ
Leuk Res; 2010 Mar; 34(3):284-8. PubMed ID: 19646755
[TBL] [Abstract][Full Text] [Related]
9. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Wierda W; O'Brien S; Wen S; Faderl S; Garcia-Manero G; Thomas D; Do KA; Cortes J; Koller C; Beran M; Ferrajoli A; Giles F; Lerner S; Albitar M; Kantarjian H; Keating M
J Clin Oncol; 2005 Jun; 23(18):4070-8. PubMed ID: 15767647
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
[TBL] [Abstract][Full Text] [Related]
12. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
13. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
Lin TS; Donohue KA; Byrd JC; Lucas MS; Hoke EE; Bengtson EM; Rai KR; Atkins JN; Link BK; Larson RA
J Clin Oncol; 2010 Oct; 28(29):4500-6. PubMed ID: 20697069
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
[TBL] [Abstract][Full Text] [Related]
16. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Reynolds C; Di Bella N; Lyons RM; Hyman W; Richards DA; Robbins GJ; Vellek M; Boehm KA; Zhan F; Asmar L
Invest New Drugs; 2012 Jun; 30(3):1232-40. PubMed ID: 21922186
[TBL] [Abstract][Full Text] [Related]
17. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Cortes J; Beran M; Koller CA; Giles FJ; Lerner S; Keating M
J Clin Oncol; 2001 Mar; 19(5):1414-20. PubMed ID: 11230486
[TBL] [Abstract][Full Text] [Related]
18. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Lin KI; Tam CS; Keating MJ; Wierda WG; O'Brien S; Lerner S; Coombes KR; Schlette E; Ferrajoli A; Barron LL; Kipps TJ; Rassenti L; Faderl S; Kantarjian H; Abruzzo LV
Blood; 2009 Apr; 113(14):3168-71. PubMed ID: 19050308
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
Byrd JC; Peterson BL; Morrison VA; Park K; Jacobson R; Hoke E; Vardiman JW; Rai K; Schiffer CA; Larson RA
Blood; 2003 Jan; 101(1):6-14. PubMed ID: 12393429
[TBL] [Abstract][Full Text] [Related]
20. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
